Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909130 | 0.75 | — | — | |
| SCHEMBL3195052 | 0.74 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL1400381 | 0.73 | DYRK1A (0.42) | CYP3A4CYP2C9CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL12487832 | 0.72 | GRIN2D (0.42) | CYP3A4CYP2C9CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL2342778 | 0.71 | PDPK1 (0.47) | CYP2A6ALDH1A1HSD17B10RAB9ANPC1 | |
| SCHEMBL4740779 | 0.71 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL7832259 | 0.69 | — | — | |
| SCHEMBL11229774 | 0.68 | MAPT (0.31) | MAPT | |
| SCHEMBL4462179 | 0.68 | PDGFRB (0.43) | KDM4EALDH1A1HPGDMEN1MAPT | |
| SCHEMBL5797199 | 0.68 | MAPT (0.43) | CYP3A4CYP2C9CYP2A6KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 278 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348392-A1 | PYRIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-02 | — | — | US | claimed |
| CN-116283478-A | Organic compound and application thereof | 阜阳欣奕华材料科技有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-20230114875-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2023-04-13 | — | — | US | claimed |
| EP-4146628-A1 | PYRIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2023-03-15 | — | — | EP | claimed |
| CN-111187220-B | Trifluoromethyl pyrimidine derivative containing Schiff base structural unit and preparation method and application thereof | 郑州大学 | 2022-08-02 | — | — | CN | claimed |
| WO-2021224220-A1 | PYRIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-11-11 | — | — | WO | claimed |
| WO-2021123237-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2021-06-24 | — | — | WO | claimed |
| EP-3652157-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-05-20 | — | — | EP | claimed |
| CN-109651343-A | A kind of Fipronil pyrazoles alcohol cyclic imides compound and its microwave-hydrothermal method method and application | 中南民族大学 | 2019-04-19 | — | — | CN | claimed |
| WO-2019012037-A1 | 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES | Grünenthal GmbH (DE) | 2019-01-17 | — | — | WO | claimed |
| US-20030099861-A1 | Efficient red organic electroluminescent devices | CITYU RESEARCH LTD. (HK) | 2003-05-29 | — | — | US | claimed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | claimed |
| EP-1265907-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | Metabasis Therapeutics, Inc. (US) | 2002-12-18 | — | — | EP | claimed |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | claimed |
| EP-0475527-B1 | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | SANOFI SA (FR) | 1998-02-25 | — | — | EP | claimed |
| EP-0809650-A1 | SERINE PROTEASE INHIBITORS | ELLERMAN PHARMACEUTICALS LIMITED (GB) | 1997-12-03 | — | — | EP | claimed |
| US-5190930-A | Calcium metabolism disorder | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | claimed |
| EP-0361341-A2 | Therapeutics for aids based on inhibitors of HIV protease | MILES INC. (US) | 1990-04-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | CYP3A4 1936/4885CYP2C9 3786/4885CYP2E1 2895/4885 |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | FBP1, SLC5A1, G6PC1 | CYP3A4 982/4885CYP2C9 660/4885CYP2E1 273/4885 |
| US-20230348392-A1 | PYRIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | PNPO, TST, TPMT | CYP3A4 56/4885CYP2C9 130/4885CYP2E1 98/4885 |
| US-20230114875-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | AARS1, ASNS, GARS1 | CYP3A4 3657/4885CYP2C9 3012/4885CYP2E1 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.